Generic Name and Formulations:
Nusinersen 12mg/5mL; soln for intrathecal inj; preservative-free.
Indications for SPINRAZA:
Spinal muscular atrophy.
Adults and Children:
Consider sedation and ultrasound or other imaging techniques as guidance. Remove 5mL of cerebrospinal fluid prior to inj. Give as intrathecal bolus inj over 1–3 mins. 12mg (5mL) per dose. Initially: give 3 loading doses at 14-day intervals then give 4th loading dose 30 days after. Maintenance: give dose once every 4 months thereafter.
Do not administer in areas of infected or inflamed skin. Increased risk of bleeding complications. Perform platelet count, prothrombin time, aPTT, quantitative spot urine protein testing at baseline, prior to each dose, and as clinically needed; consider repeat testing if urine protein >0.2g/L. Pregnancy. Nursing mothers.
Lower/upper respiratory infection, constipation, teething, UTI, ear infection; thrombocytopenia, coagulation abnormalities, renal toxicity.
Neurology Advisor Articles
- Epilepsy's Mobility Problem: Advocating for Changes in Transportation Laws, Public Resources
- The Future of Freezing of Gait in Parkinson's: Exploring Potential Treatments and Preventive Strategies
- Efficacy of Cladribine Tablets in Patients With Relapsing Multiple Sclerosis
- Mirtazapine for Fibromyalgia: An Effective Treatment Option?
- Some Common Allergies Linked to Odds of Autism in Children
- Polyphenol-Rich Diet May Reduce Dementia Risk in Older Adults
- Addressing Migraine That Mimics Stroke
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Visual Association Test, MMSE Highly Predictive of Dementia in Older Adults
- Medical Cannabis Shows Promise in Treating Symptoms of Multiple Sclerosis
- Patients' Preferences for Physician Attire Linked to Perception of Care
- IV Fluid Specs Do Not Influence Neuro Outcomes in Kids w/DKA
- Acute Insomnia Found to Be Common Among Good Sleepers
- Cognitive Performance, Mood Deficits, White Matter Hyperintensities in Migraine
- Focal Brain Atrophy Predicts Cognitive Decline in Parkinson Disease After DBS